Correlation Between Werewolf Therapeutics and Crinetics Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Werewolf Therapeutics and Crinetics Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Werewolf Therapeutics and Crinetics Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Werewolf Therapeutics and Crinetics Pharmaceuticals, you can compare the effects of market volatilities on Werewolf Therapeutics and Crinetics Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Werewolf Therapeutics with a short position of Crinetics Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Werewolf Therapeutics and Crinetics Pharmaceuticals.

Diversification Opportunities for Werewolf Therapeutics and Crinetics Pharmaceuticals

0.84
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Werewolf and Crinetics is 0.84. Overlapping area represents the amount of risk that can be diversified away by holding Werewolf Therapeutics and Crinetics Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crinetics Pharmaceuticals and Werewolf Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Werewolf Therapeutics are associated (or correlated) with Crinetics Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crinetics Pharmaceuticals has no effect on the direction of Werewolf Therapeutics i.e., Werewolf Therapeutics and Crinetics Pharmaceuticals go up and down completely randomly.

Pair Corralation between Werewolf Therapeutics and Crinetics Pharmaceuticals

Given the investment horizon of 90 days Werewolf Therapeutics is expected to generate 2.55 times less return on investment than Crinetics Pharmaceuticals. In addition to that, Werewolf Therapeutics is 1.56 times more volatile than Crinetics Pharmaceuticals. It trades about 0.01 of its total potential returns per unit of risk. Crinetics Pharmaceuticals is currently generating about 0.05 per unit of volatility. If you would invest  1,964  in Crinetics Pharmaceuticals on November 19, 2024 and sell it today you would earn a total of  1,557  from holding Crinetics Pharmaceuticals or generate 79.28% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Werewolf Therapeutics  vs.  Crinetics Pharmaceuticals

 Performance 
       Timeline  
Werewolf Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Werewolf Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unsteady performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.
Crinetics Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Crinetics Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Werewolf Therapeutics and Crinetics Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Werewolf Therapeutics and Crinetics Pharmaceuticals

The main advantage of trading using opposite Werewolf Therapeutics and Crinetics Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Werewolf Therapeutics position performs unexpectedly, Crinetics Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crinetics Pharmaceuticals will offset losses from the drop in Crinetics Pharmaceuticals' long position.
The idea behind Werewolf Therapeutics and Crinetics Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated